APELLIS Aktie

>APELLIS Aktienkurs

23.45 EUR -2.4% (Tradegate)

Ask: 23.715 EUR / 70 Stück

Bid: 23.45 EUR / 80 Stück

Tagesumsatz: 209 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

APELLIS Aktie über LYNX handeln

Intraday

1 Jahr

>APELLIS Performance

1 Woche: -0,7%

1 Monat: +46,3%

3 Monate: +53,2%

6 Monate: -1,9%

1 Jahr: -34,9%

laufendes Jahr: -24,7%

>APELLIS Aktie

Name:

APELLIS PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US03753U1060 / A2JAAW

Symbol/ Ticker:

1JK (Frankfurt) / APLS (NASDAQ)

Kürzel:

FRA:1JK, ETR:1JK, 1JK:GR, NASDAQ:APLS

Index:

Webseite:

https://www.apellis.com/

Profil:

Apellis Pharmaceuticals Inc. is a biopharmaceutica..
>Volltext..

Marktkapitalisierung:

2979.66 Mio. EUR

Unternehmenswert:

3063.05 Mio. EUR

Umsatz:

645.81 Mio. EUR

EBITDA:

-161.11 Mio. EUR

Nettogewinn:

-195.27 Mio. EUR

Gewinn je Aktie:

-1.56 EUR

Schulden:

402.02 Mio. EUR

Liquide Mittel:

317.89 Mio. EUR

Operativer Cashflow:

3.84 Mio. EUR

Bargeldquote:

1.85

Umsatzwachstum:

9.13%

Gewinnwachstum:

37.68%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 6.491.743 USD.

Suchwörter:

APELLIS

Letzte Datenerhebung:

30.08.25

>APELLIS Kennzahlen

Aktien/ Unternehmen:

Aktien: 126.29 Mio. St.

Frei handelbar: 82.24%

Leerverk. Aktien: 16.3%

Rückkaufquote: -0.32%

Mitarbeiter: 710

Umsatz/Mitarb.: 0.94 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 38.43%

Bewertung:

KGV: -

KGV lG: 82.54

KUV: 4.7

KBV: 22.36

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 83.6%

Gewinnmarge: -30.24%

Operative Marge: -25.18%

Managementeffizenz:

Gesamtkaprendite: -26.44%

Eigenkaprendite: -108.49%

>APELLIS Peer Group

Es sind 601 Aktien bekannt.

>APELLIS Chart & Kurs - NASDAQ

>APELLIS News

30.08.25 - 01:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 4934293 USD (Insiderkauf)
	Francois, Cedric - Vorstand - Tag der Transaktion: 2025-08-27...

30.08.25 - 01:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 1418450 USD (Insiderkauf)
	Francois, Cedric - Vorstand - Tag der Transaktion: 2025-08-28...

27.08.25 - 13:03	Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:...

20.08.25 - 01:01	Insiderhandel: General Counsel verkauft Aktien von Apellis Pharmaceuticals im Wert von 139000 USD (Insiderkauf)
	Watson, David O. - Vorstand - Tag der Transaktion: 2025-08-18...

31.07.25 - 16:45	Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
	The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....

31.07.25 - 13:09	Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results (GlobeNewswire EN)
	WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its second quarter 2025 financial results and business highlights....

30.07.25 - 18:09	Apellis Pharmaceuticals Q2 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.25 - 20:12	Apellis wins FDA label expansion for Empaveli in rare kidney disorders (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.25 - 01:21

FDA Approves Apellis′ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older (GlobeNewswire EN)

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1...

24.07.25 - 13:03	Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results (GlobeNewswire EN)
	WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET....

19.07.25 - 03:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 398735 USD (Insiderkauf)
	Francois, Cedric - Vorstand - Tag der Transaktion: 2025-07-17...

19.07.25 - 03:01	Insiderhandel: General Counsel verkauft Aktien von Apellis Pharmaceuticals im Wert von 97750 USD (Insiderkauf)
	Watson, David O. - Vorstand - Tag der Transaktion: 2025-07-16...

17.07.25 - 02:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 38168 USD (Insiderkauf)
	Francois, Cedric - Vorstand - Tag der Transaktion: 2025-07-15...

17.07.25 - 02:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 2774923 USD (Insiderkauf)
	Francois, Cedric - Vorstand - Tag der Transaktion: 2025-07-14...

15.07.25 - 13:03

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting (GlobeNewswire EN)

WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 30 - August 2 in Long Beach, California. These data further demonstrate the robust efficacy and well-documented safety profile of SYFOVRE® (pegcetacoplan injection) for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)....

02.07.25 - 18:15	Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli (Zacks)
	APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects....

01.07.25 - 15:06	Apellis signs royalty purchase deal with Sobi for Aspaveli (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.07.25 - 13:45	Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan) (PR Newswire)
	STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275......

01.07.25 - 13:03

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) (GlobeNewswire EN)

WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $300 million in exchange for 90% of Apellis' future ex-U.S. royalties for Aspaveli® (systemic pegcetacoplan). Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI®....

18.06.25 - 16:01	Insiderhandel: General Counsel verkauft Aktien von Apellis Pharmaceuticals im Wert von 93850 USD (Insiderkauf)
	Watson, David O. - Vorstand - Tag der Transaktion: 2025-06-16...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Humorist lustwandelt innerhalb der Unendlichkeit. - Arthur Schnitzler

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram